Maplelane Capital’s Royalty Pharma RPRX Stock Holding History

Maplelane Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-400,000	Closed	-$20M	–	170
2020 Q4	$20M	Buy	+400,000	New	+$17M	0.25%	87

Other funds holding RPRX

RWJF

Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Maplelane Capital's RPRX Position: Q1 2021 in Review

Maplelane Capital sold out of Royalty Pharma (RPRX) in Q1 2021, closing a stake of 1 share.

Maplelane Capital first reported a position in RPRX in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 214 funds tracked by Wall St. Rank hold RPRX as of Q1 2021.

Maplelane Capital reported no remaining Royalty Pharma position as of Q1 2021 after selling out during the quarter.
Maplelane Capital sold 1 Royalty Pharma share in Q1 2021.
Maplelane Capital first reported a position in Royalty Pharma in Q4 2020 and held it in 1 quarter.
Maplelane Capital's Royalty Pharma position peaked at $0 in Q4 2020.
214 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2021.

Based on Maplelane Capital's 13F filing for Q1 2021, filed 17 May 2021.